ロード中...
P53 inhibition exacerbates late-stage anthracycline cardiotoxicity
AIMS: Doxorubicin (DOX) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage cardiotoxicity. Children are particularly sensitive to DOX-induced heart failure. Here, the impact of p53 inhibition on acute vs. late-stage DOX cardiotoxicity was examined in a juvenile...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4133592/ https://ncbi.nlm.nih.gov/pubmed/24812279 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cvr/cvu118 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|